Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.

By P. Ridker, Jean G Macfadyen, Brendan M. Everett, Peter Libby, T. Thuren, Robert J. Glynn. The Lancet, 2017

783 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/f04c81e5ad504a3e0f80b0bb27b751e2a585e4c5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. E. Latz

In Molecular Biology

1. A. Grebe
2. E. Latz
3. Florian Hoss

Citations in the corpus

• NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. (2018, result): “Furthermore, a secondary analysis of the CANTOS trial data confirmed the previously established positive correlation between the magnitude of CRP reduction with cardiovascular event reduction also for canakinumab treatment.(212) These findings even suggest that the extent of CRP reduction after the ”